AZN : Phase III Trial Of Imfinzi On Recurrent Or Metastatic Head & Neck Cancer Fails To Meet Goal

(RTTNews) – AstraZeneca Plc. (AZN.L, AZN) said that a late-stage trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer did not meet the primary as well as secondary endpoints.As per the Kestrel Phase III trial resuRead MoreMarketsMarkets Feed

¡Haz clic para votar esta entrada!
(Votos: 0 Promedio: 0)

Deja un comentario